Drug Shortage Report for CLINDAMYCIN INJECTION IN 5% DEXTROSE
Report ID | 177050 |
Drug Identification Number | 02485478 |
Brand name | CLINDAMYCIN INJECTION IN 5% DEXTROSE |
Common or Proper name | CLINDAMYCIN INJECTION IN 5% DEXTROSE |
Company Name | BAXTER CORPORATION |
Market Status | MARKETED |
Active Ingredient(s) | CLINDAMYCIN |
Strength(s) | 600MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 50mL |
ATC code | J01FF |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2022-12-02 |
Actual start date | 2022-12-02 |
Estimated end date | 2022-12-12 |
Actual end date | 2022-12-12 |
Shortage status | Resolved |
Updated date | 2022-12-12 |
Company comments | Baxter products Clindamycin Injection in 5% Dextrose 300 mg / 50 mL (DIN : 02485451) & Clindamycin Injection in 5% Dextrose 900 mg / 50 mL (DIN : 02485486) are available as alternatives if they align with clinical practice. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-12-12 | French | Compare |
v5 | 2022-12-12 | English | Compare |
v4 | 2022-12-03 | English | Compare |
v3 | 2022-12-02 | French | Compare |
v2 | 2022-12-02 | English | Compare |
v1 | 2022-12-02 | English | Compare |
Showing 1 to 6 of 6